What makes a successful merger? Here we look at the 2018 merger between genome-therapy-focused company Sangamo Therapeutics and TxCell, which focuses on regulatory T-cell (Treg) development for immunological diseases.
According to the inaugural annual report from the International Society for Cell and Gene Therapy (ISCT), the number of CGTs with marketing authorization increased by 45 percent between 2015 and September 2018.
Real-world evidence is playing an increasingly important role throughout the drug development lifecycle—as outlined in Deloitte's latest survey on the life sciences industry's RWE capabilities— and companies are really beginning to take notice.
Falsified medicines are a critical challenge to the safety of patients and to the reputation of the pharmaceutical industry. Serialization is a major step toward drug safety across the EU but has brought with it a set of challenges that national authorities and companies are tackling.
In 2018, seven French bioclusters announced they were planning to work more closely together to, among other things, improve the attractiveness of France for medical and pharma science and re-industrialize the country.
Sweden's approach to maintaining innovation and effectiveness in drug development relies on precision medicine, as outlined in the new SwedenBIO report "Precision Medicine – The Swedish Industry Guide 2018."
The "State of the Discovery Nation 2018" report is based on surveys and more than 100 in-depth interviews with senior executives at U.K. drug-discovery companies. The report looks at the current status of U.K. drug discovery and its challenges and opportunities.